| 2015 | Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea | 배승진 | Article |
| 2021 | Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea | 배승진 | Article |
| 2014 | Sourcing quality-of-life weights obtained from previous studies: Theory and reality in Korea | 배승진 | Review |
| 2019 | Statistical analysis of the reproducibility and predictive capacity of MCTT HCE (TM) eye irritation test, a me-too test method for OECD TG 492 | 배승진; 임경민; 이동환 | Article |
| 2014 | Suppression of skin inflammation in keratinocytes and acute/chronic disease models by caffeic acid phenethyl ester | 배승진; 임경민 | Article in Press |
| 2020 | The Burden of Cervical Cancer in Korea: A Population-Based Study | 배승진; 이동환; 손경복 | Article |
| 2021 | The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future | 배승진 | Article |
| 2022 | The Impact of Payment Scheme Changes on Medication Adherence and Persistence of Patients Diagnosed with Depression in Korea | 배승진; 배그린 | Article |
| 2022 | The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS | 배승진 | Article |
| 2024 | Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study | 배승진; 신경선 | Article |
| 2020 | Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? | 배승진 | Article |
| 2019 | Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients | 배승진; 손경복 | Article |
| 2021 | Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology | 배승진; 이동환; 배그린 | Article |
